how long they've been dogging us !!!
You have to admit it is very compelling. Revenues have to sky rocket. Imagine if results show no advantage to CHEMO and the FDA makes it a first line treatment too? Crazy stuff. Just the possibility can make this stock run emotionally.
wouldn't be surprised if they were the same person. The reality is we have a long way to go. Financing is a hurdle. The fact we had 10% more sales...ok. I think the automated processing will cut costs but not enough to just cut.... we need a rise in revenues. I think the more MD's see the difference in results the more play we can get. By automating the process perhaps we can reduce the price therefore make money on less revenue but obviously more revenue. If we are cheaper than the pills we will get first call. Be interesting to see if we are getting more off label useage or any new treatment regimens at the conference. Seems like we are doing better. Not by much though. I think a partner or buyer would be the best solution now. I had enough but won't sell until I share in the glory. Not going up without me. My recommendation to the rest of you as well. Good luck.
in light of the blackrock purchase. I would imagine there would have been upward pressure. Either Blackrock is stupid or they have created another bear trap. We all know Blackrock is savvy.
Novartis AG (NOVN) has a promising therapy for cancer. It’s just not sure how to get it to patients easily.
The treatment is so potent that it cleared malignant cells in about 90 percent of patients facing almost certain death from the most common form of cancer in children.
The approach involves taking T cells, part of the body’s immune system, from the blood and engineering them to identify proteins on cancer cells. When returned to the patient’s bloodstream, the revamped T cells seek and destroy cancer cells. It’s so specific that a single mistake can mean death for a patient, and so turbo-charged that Novartis plans to set up a network of hospitals versed in treating the spiking fever, chills and flu-like symptoms that may come as side effects.
“The question is really if this is the right way to go at immunotherapy,” a burgeoning field of medicine that empowers the immune system to fight diseases such as cancer, Michael Leuchten, an analyst at Barclays Plc in London, said in an interview.
Cancer cells can use proteins on their surfaces as biological cloaks of invisibility to elude detection by the immune-system cells policing the body. Immunotherapies include checkpoint agents, drugs that strip away such disguises and expose cancer cells to attack; products such as Dendreon Corp. (DNDN)’s Provenge, which combines a patient’s immune cells with vaccine components in an infusion; and so-called biconjugated antibodies that help immune cells anchor themselves to cancerous ones.
at .02 above the bid and ask. What are you guys trading 100's of shares. OK a few of you 1000 shares?
give it the know it all rhetoric a break. Watch the money flow.
sounds like fear to me. They are desperately trying to cover. They even short more to shake loose shares.
Think that means anything? I'm long DNDN and don't think Allergan is the buyer. I can't even access that website domain so it must be inactive. Maybe at one time Allergan was thinking about or talks to acquire. I think Novartis is more likely candidate with the need for their immuno brain cancer delivery system.
guess what's coming.....buy out!!!
I did. $7 then averaged at 4.83. Don't think it will be the last time it hits $7. Would short this stock. Too much upside.